We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mersana Therapeutics Inc | NASDAQ:MRSN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.21 | 6.07% | 3.67 | 2.96 | 3.88 | 3.59 | 3.46 | 3.52 | 694,527 | 23:02:46 |
Guggenheim Oncology Conference | |
Format: | Fireside Chat |
Date/Time: | Wednesday, February 8, 2023, at 2:10 p.m. Eastern Time |
SVB Securities Global Biopharma Conference | |
Format: | Fireside Chat |
Date/Time | Wednesday, February 15, 2023, at 1:00 p.m. Eastern Time |
Cowen 43rd Annual Health Care Conference | |
Format: | Panel Discussion |
Date/Time: | Wednesday, March 8, 2023, at 9:10 a.m. Eastern Time |
Oppenheimer 33rd Annual Healthcare Conference | |
Format: | Presentation |
Date/Time: | Tuesday, March 14, 2023, at 12:00 p.m. Eastern Time |
Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.
About Mersana TherapeuticsMersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi in combination with carboplatin; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:Jason Fredette 617-498-0020jason.fredette@mersana.com
1 Year Mersana Therapeutics Chart |
1 Month Mersana Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions